Trial Profile
Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Carboplatin
- Indications Advanced breast cancer; Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer; Gastrointestinal cancer; Gynaecological cancer; Head and neck cancer; Lung cancer; Sarcoma; Solid tumours; Squamous cell cancer; Tongue cancer; Urogenital cancer
- Focus Adverse reactions
- Sponsors Sun Pharma Advanced Research Company
- 20 Oct 2016 Status changed from recruiting to completed.
- 08 Mar 2016 Planned End Date changed from 1 Apr 2016 to 1 Jul 2016, according to ClinicalTrials.gov record.
- 08 Mar 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jun 2016, according to ClinicalTrials.gov record.